NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

Recruiting

Conditions: Macrophage Activation Syndrome
Hyperinflammatory Syndromes
Lymphohistiocytosis, Hemophagocytic
Secondary Hemophagocytic Lymphohistiocytosis

First Posted Date: 2024-04-01

Last Posted Date: 2024-12-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT06339177

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Phase 1

Not yet recruiting

Conditions: HIV-1-infection
Pregnancy
Postpartum

Interventions: Drug: CAB LA 600mg
Drug: CAB LA 400mg
Drug: RPV LA 900mg
Drug: RPV LA 600mg

First Posted Date: 2024-03-28

Last Posted Date: 2024-11-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT06336434

Locations: 🇺🇸
Site 4601, University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States
🇺🇸
Site 5048, University of Southern California LA, Los Angeles, California, United States
🇺🇸
Site 5013, Jacobi Medical Center Bronx, Bronx, New York, United States

and more 5 locations

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

Phase 1

Active, not recruiting

Conditions: HIV

Interventions: Biological: 16055 NFL delta Gly4 trimer
Biological: Trimer 4571
Biological: Ad4-Env145NFL, 5 x 108 viral particles (vp)

First Posted Date: 2024-03-27

Last Posted Date: 2024-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT06332339

Locations: 🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
🇺🇸
The Hope Clinic of the Emory Vaccine Center CRS Site# 31440, Decatur, Georgia, United States

and more 3 locations

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Phase 1

Recruiting

Conditions: Chronic Granulomatous Disease (CGD)
X-Linked Chronic Granulomatous Disease

Interventions: Biological: Base-edited hematopoietic stem and progenitor cells
Drug: Busulfan
Drug: Palifermin
Drug: Filgrastim
Drug: Plerixafor

First Posted Date: 2024-03-22

Last Posted Date: 2024-12-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT06325709

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

Phase 2

Recruiting

Conditions: Liver Transplant

Interventions: Drug: Tacrolimus (maintain 50% reduction)
Drug: Everolimus
Drug: Tacrolimus (continued reduction)

First Posted Date: 2024-02-28

Last Posted Date: 2024-11-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 340

Registration Number: NCT06280950

Locations: 🇺🇸
Mayo Clinic Hospital Arizona (Site #: 71144), Phoenix, Arizona, United States
🇺🇸
University of California, San Francisco (Site #: 71108), San Francisco, California, United States
🇺🇸
Northwestern University (Site #: 71110), Chicago, Illinois, United States

and more 5 locations

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

Phase 1

Not yet recruiting

Conditions: HIV

Interventions: Biological: CD4BS CH505M5 Pr-NP1
Biological: CH505TF chTrimer
Biological: ACU-026-001-1 (labeled as empty LNP)
Biological: 3M-052-AF (labeled as AP 60-702)
Biological: Aluminum Hydroxide Suspension (Alum)

First Posted Date: 2024-02-20

Last Posted Date: 2024-06-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 42

Registration Number: NCT06267872

Locations: 🇺🇸
Alabama CRS (Site ID: 31788), Birmingham, Alabama, United States
🇿🇦
Setshaba Research Centre CRS (Site ID: 31829), Soshanguve, Gauteng, South Africa
🇿🇦
Isipingo CRS (Site ID: 31635), Isipingo, Kwa Zulu Natal, South Africa

and more 3 locations

pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)

Phase 1

Conditions: p47
Autosomal Recessive
Chronic Granulomatous Disease

Interventions: Biological: Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47

First Posted Date: 2024-02-12

Last Posted Date: 2024-12-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT06253507

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Phase 2

Not yet recruiting

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Bedaquiline
Drug: Pyrazinamide
Drug: Pretomanid
Drug: Ethambutol
Drug: Linezolid
Drug: TBI-223
Drug: Sutezolid

First Posted Date: 2024-01-05

Last Posted Date: 2024-11-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 315

Registration Number: NCT06192160

Locations: 🇺🇬
12401, Joint Clinical Research Centre (JCRC)/Kampala CRS, Kampala, Uganda
🇲🇼
30301, Blantyre CRS, Blantyre, Malawi
🇲🇼
12001, Malawi CRS, Lilongwe, Malawi

and more 21 locations

Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity

Recruiting

Conditions: Nervous System Disease
Immune System Disease

First Posted Date: 2023-12-13

Last Posted Date: 2024-10-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 350

Registration Number: NCT06169150

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Investigation of Immune Amnesia Following Measles Infection in Select African Regions

Recruiting

Conditions: Measles Infection

Interventions: Biological: Verorab

First Posted Date: 2023-12-01

Last Posted Date: 2024-11-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 256

Registration Number: NCT06153979

Locations: 🇲🇱
University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
🇬🇳
Partnership of Clinical Research in Guinea, Partenariat Pour La Recherche Clinique en Guinée (PREGUI), Conakry, Guinea

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy